NVS

Novartis
D

NVS

Arincen80/100B

Novartis balance sheet 1998–2026

Novartis had 8.98B USD in cash and short-term investments on 30 September 2026, against total debt of 48.31B USD: net debt of 39.34B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
8.87B11.44B11.46B13.39B7.52B12.41B9.66B11.11B13.27B8.86B7.01B
Short-term investments
105.00M155.00M1.89B569.00M11.10B15.71B1.91B334.00M2.69B625.00M770.00M
8.98B11.59B13.35B13.96B18.62B28.11B11.56B11.45B15.96B9.49B7.78B
Cash growth
-7.98%-13.19%-4.38%-25.00%-33.79%+143.13%+1.02%-28.30%+68.31%+21.96%+42.78%
Receivables
9.96B10.93B8.21B9.38B9.89B9.62B9.07B9.17B9.68B10.07B10.20B
Inventory
6.10B6.27B5.72B5.91B7.18B6.67B7.13B5.98B6.96B6.87B6.26B
Other current assets
3.71B514.00M1.43B466.00M315.00M216.00M963.00M2.01B3.23B1.03B0.00
Total current assets
28.75B30.46B29.70B30.48B36.91B45.72B29.67B29.50B35.56B28.21B24.93B
Property, plant and equipment
12.27B12.35B10.87B10.92B12.20B13.11B13.94B13.75B15.70B16.46B15.64B
Long-term investments
2.10B2.30B1.13B1.83B1.61B2.27B12.44B11.00B10.70B17.61B16.50B
Goodwill and intangibles
67.00B54.98B51.67B50.22B60.95B63.78B66.81B55.31B74.01B61.75B62.32B
Goodwill
27.18B25.57B24.76B23.34B29.30B29.60B30.00B26.52B35.29B31.75B30.98B
Intangible assets
39.83B29.41B26.92B26.88B31.64B34.18B36.81B28.79B38.72B30.00B31.34B
Other non-current assets
1.69B5.42B4.51B2.18B2.06B3.18B981.00M897.00M895.00M818.00M698.00M
Total assets
117.15B115.57B102.25B99.95B117.45B131.80B132.19B118.41B145.56B133.08B130.12B
Accounts payable
4.24B4.46B4.57B4.93B5.15B5.55B5.40B5.42B5.56B5.17B4.87B
Deferred revenue
0.000.00127.00M98.00M123.00M123.00M56.00M114.00M236.00M305.00M287.00M
Short-term debt
9.65B5.78B8.09B6.08B5.88B6.23B9.88B7.09B9.62B5.20B5.91B
Other current liabilities
15.70B12.82B10.38B9.84B11.21B12.44B12.98B10.98B9.63B8.68B9.15B
Total current liabilities
32.53B27.28B28.69B26.39B28.66B30.21B33.06B28.26B29.61B23.40B22.21B
Long-term debt
36.70B29.59B21.37B18.44B20.24B22.90B26.26B20.35B22.47B23.22B17.90B
Other non-current liabilities
4.28B2.48B4.08B4.52B4.91B6.17B6.93B6.63B8.85B6.55B8.03B
Lease obligations, current
278.00M0.00235.00M230.00M251.00M275.00M0.000.000.000.002.15B
Lease obligations, long-term
1.68B1.66B1.57B1.60B1.54B1.62B1.72B1.70B0.000.0082.00M
Total liabilities
79.59B69.02B58.12B53.20B58.03B63.97B75.52B62.86B66.87B58.85B55.23B
Common stock and paid-in capital
736.00M766.00M793.00M825.00M890.00M901.00M913.00M936.00M944.00M969.00M972.00M
Retained earnings
39.24B44.72B46.56B49.65B63.54B70.99B57.16B59.27B82.19B77.64B81.15B
Accumulated other comprehensive income
-2.69B694.00M-3.26B-3.77B-5.00B-4.19B-1.42B-4.66B77.74B73.30B73.94B
Shareholders' equity
37.23B46.13B44.05B46.67B59.34B67.66B56.60B55.47B78.61B74.17B74.83B
Minority interest
336.00M419.00M80.00M83.00M81.00M167.00M68.00M77.00M78.00M59.00M59.00M
48.31B35.38B31.26B26.35B27.91B31.03B37.86B29.15B32.09B28.43B23.80B
Net cash
-39.34B-23.79B-17.91B-12.39B-9.29B-2.91B-26.29B-17.70B-16.13B-18.94B-16.03B
Working capital
-3.78B3.18B1.01B4.09B8.25B15.51B-3.39B1.24B5.96B4.81B2.72B
Book value per share
19.5423.6021.6422.3127.0129.9424.6523.9233.5431.2831.18
Tangible book value
-29.77B-8.85B-7.63B-3.55B-1.60B3.88B-10.21B163.00M4.60B12.42B12.51B
Tangible book value per share
-15.63-4.53-3.75-1.70-0.731.72-4.450.071.965.245.21
Current ratio
0.881.121.041.161.291.510.901.041.201.211.12
Debt to equity
1.300.770.710.560.470.460.670.530.410.380.32

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Novartis's cash and debt

Source: Financial Modeling Prep